Leerink Partnrs Analysts Lift Earnings Estimates for Xencor

Key Points

• Leerink Partners raised their Q3 2025 earnings per share (EPS) estimate for Xencor to ($0.74), up from the previous forecast of ($0.76), while the consensus full-year estimate is ($3.68) EPS.
• Xencor reported Q3 earnings of ($0.41), surpassing expectations by $0.37, with revenues of $43.61 million, significantly higher than the forecast of $22.59 million.
• Analyst ratings are mixed, with two analysts issuing sell ratings and seven assigning a buy rating, resulting in an average rating of "Moderate Buy" and a consensus price target of $26.43.

Xencor, Inc. (NASDAQ:XNCR - Free Report) - Equities researchers at Leerink Partnrs upped their Q3 2025 earnings per share (EPS) estimates for shares of Xencor in a research report issued on Wednesday, August 6th. Leerink Partnrs analyst J. Chang now anticipates that the biopharmaceutical company will earn ($0.74) per share for the quarter, up from their prior forecast of ($0.76). The consensus estimate for Xencor's current full-year earnings is ($3.68) per share. Leerink Partnrs also issued estimates for Xencor's Q4 2025 earnings at ($0.95) EPS, FY2025 earnings at ($2.76) EPS and FY2026 earnings at ($3.18) EPS.

Several other research firms also recently weighed in on XNCR. William Blair initiated coverage on Xencor in a research report on Monday, April 21st. They issued an "outperform" rating on the stock. Wedbush reduced their target price on Xencor from $31.00 to $26.00 and set an "outperform" rating on the stock in a research report on Thursday, August 7th. Barclays lowered their target price on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a research note on Thursday, May 8th. Finally, Wells Fargo & Company cut their price objective on Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a report on Thursday, August 7th. Two analysts have rated the stock with a sell rating and seven have given a buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $26.43.

Xencor Stock Performance

Xencor stock traded down $0.29 during midday trading on Monday, hitting $7.44. 194,560 shares of the company were exchanged, compared to its average volume of 767,628. The firm has a market capitalization of $530.26 million, a PE ratio of -3.13 and a beta of 0.89. Xencor has a fifty-two week low of $6.92 and a fifty-two week high of $27.24. The business has a fifty day simple moving average of $8.58 and a two-hundred day simple moving average of $10.74.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.78) by $0.37. Xencor had a negative return on equity of 25.75% and a negative net margin of 121.52%. The company had revenue of $43.61 million during the quarter, compared to analysts' expectations of $22.59 million. During the same period last year, the business posted ($1.07) earnings per share. The firm's revenue was up 82.4% compared to the same quarter last year.

Insider Transactions at Xencor

In other Xencor news, Director Ellen Feigal sold 2,993 shares of the stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. This represents a 13.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Kurt A. Gustafson sold 2,993 shares of the stock in a transaction on Monday, June 16th. The stock was sold at an average price of $9.22, for a total transaction of $27,595.46. Following the transaction, the director directly owned 20,183 shares in the company, valued at $186,087.26. The trade was a 12.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 11,194 shares of company stock valued at $103,209 over the last quarter. Company insiders own 4.76% of the company's stock.

Hedge Funds Weigh In On Xencor

A number of institutional investors have recently made changes to their positions in the business. Sterling Capital Management LLC increased its holdings in shares of Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 1,040 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Xencor in the fourth quarter valued at approximately $34,000. State of Wyoming acquired a new stake in shares of Xencor in the first quarter valued at approximately $34,000. CWM LLC increased its holdings in shares of Xencor by 195.5% in the first quarter. CWM LLC now owns 3,372 shares of the biopharmaceutical company's stock valued at $36,000 after purchasing an additional 2,231 shares in the last quarter. Finally, PNC Financial Services Group Inc. increased its holdings in shares of Xencor by 82.8% in the second quarter. PNC Financial Services Group Inc. now owns 5,982 shares of the biopharmaceutical company's stock valued at $47,000 after purchasing an additional 2,709 shares in the last quarter.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.